Limitation◼ Source of Information➢ Interviews with industry experts and competitors will be conducted on a besteffort basis to collect information for indepth analysis for this report.➢ Frost & Sullivan will not be responsible for any information gaps where Interviewees have refused to disclose confidential data or figures. ➢ The study took 2020 as the base year for analysis and 2021-2031 for forecast. However, as the point of this study being the beginning of 2021, some of the figures of 2020 may not be available at the moment from public statistical sources. Frost & Sullivan will use the latest information available (e.g. 2020) or make projections based on historical trends. ➢ Under circumstances where information is not available, Frost & Sullivan in-house analysis will be leveraged using appropriate models and indicators to arrive at an estimate. ➢ Sources of information and data will be clearly stated in the bottom right hand corner on each slide for reference. Sources and Assumptions➢ Frost & Sullivan is a global consulting company and an independent third party. Founded in 1961, ithas 40 offices worldwide with over 2,000 industry consultants, market research analysts andeconomists. In preparing the Industry Report, we conducted both primary and secondary research to obtaininformation from various sources. Primary research involved discussing the status of the industry withleading industry participants and industry experts; and secondary research involved reviewing companyreports, independent research reports and data based on our own research database. In compiling andpreparing the Industry Report, Frost & Sullivan assumed that (1) Global and China’s economy is likely tomaintain steady growth in the next decade; (2) Global and China’s social, economic, and politicalenvironment is likely to remain stable in the forecast period; (3) market drivers like increasing healthcaredemand and growing vaccine supply and innovative technology are likely to drive Global and China’svaccine market; (4) market drivers like local vaccine development and encouraging policy is likely todrive China’s HPV vaccine, COVID-19 vaccine, Norovirus vaccine, RSV vaccine and VZV vaccinemarket; and (5) all the data and information regarding the Company is provided by the Company itself.
关注公众号
安卓客户端
发表评论
注册或登后即可发表评论
登录注册
全部评论(0)